NanoViricides CEO Gives Update on Preclinical Progress for NV-387 Antiviral
NanoViricides CEO said NV-387 has shown promising broad-spectrum antiviral activity in preclinical tests and that the company is advancing toward an Investigational New Drug application targeting mid-2026. He also noted expansion of cGMP manufacturing capacity to support planned Phase 1 trials.
1. Preclinical Efficacy
The CEO highlighted that NV-387 demonstrated potent inhibition across multiple viral strains in both cell-based assays and animal models, underscoring its broad-spectrum potential against emerging pathogens.
2. Development Milestones
NanoViricides is finalizing GLP toxicology studies and preparing an IND submission targeted for mid-2026, with cGMP manufacturing capacity being expanded to meet projected needs for the initiating Phase 1 clinical trial.
Related News
FDS
Nvidia Q1 Revenue Soars 85% to $81.6B as Buyback Approved
FDS•
AVGO
Nvidia Predicts $91B Q3 Sales, Boosts Dividend and $80B Buyback; Broadcom Poised for AI Inference Growth
AVGO•
LCLN
Lincoln International Debuts 12.6% Up, Valued at $2.3 Billion After $421M IPO
LCLN•
NVDA
Nvidia Targets $200 Billion Agentic AI Market with Vera CPU Launch
NVDA•
TSLA
Tesla Earns $890 Million From SpaceX and xAI With $131M Cybertruck Deal
TSLA•
Sources
F